<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711564</url>
  </required_header>
  <id_info>
    <org_study_id>23618724</org_study_id>
    <nct_id>NCT04711564</nct_id>
  </id_info>
  <brief_title>The Effects of Different Lipid Emulsions on the Adipokines in Critically Ill Patients With Sepsis</brief_title>
  <official_title>The Effects of Different Lipid Emulsions on the Adipokines, Inflammatory Markers and Mortality in Critically Ill Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karadeniz Technical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turkish Society of Clinical Enteral &amp; Parenteral Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karadeniz Technical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous lipid emulsions contain a number of biologically active ingredients, but the most&#xD;
      important are fatty acids. Different fatty acids can affect a number of different&#xD;
      physiological processes in different ways in critically ill patients. Adipose tissue can play&#xD;
      an important role in metabolic changes of critical illnesses and in adaptation to stress&#xD;
      through structural as well as functional changes Although it is known that serum adipokine&#xD;
      and cytokine response changes in critical sepsis patients, the factors affecting these&#xD;
      changes and the metabolic consequences of these changes are not well defined. The aim of this&#xD;
      study was to evaluate the effects of intravenous lipid emulsions on serum adipokine and&#xD;
      cytokine levels in patients with sepsis. Secondly, this is to determine the adipokine and&#xD;
      cytokine kinetics in the sepsis process and their relationship with mortality in patients&#xD;
      with sepsis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">March 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the adipokine in the first ten days in onset sepsis</measure>
    <time_frame>Baseline and 10 days</time_frame>
    <description>Adipokines levels are assayed using a enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit length of stay</measure>
    <time_frame>Time of admission to the ICU until the time of discharge from the intensive care unit, up to 1 year</time_frame>
    <description>Time from study inclusion to intensive care unit discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 day</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Provision of olive oil emulsions in PN</arm_group_label>
    <description>Olive oil-based (Oliclinomel: 80% OO, 20% LCT provided in a complete all-in-one PN bag by Baxter) parenteral nutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Provision of soybean emulsions in PN</arm_group_label>
    <description>Soybean-based (Kabiven: 100% LCT provided in a complete all-in-one PN bag)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olive oil-based intravenous fat emulsions</intervention_name>
    <description>Parenteral nutrition planned according to the requirements of the patients is given for ten days.</description>
    <arm_group_label>Provision of olive oil emulsions in PN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Soybean-based intravenous fat emulsions</intervention_name>
    <description>Parenteral nutrition planned according to the requirements of the patients is given for ten days.</description>
    <arm_group_label>Provision of soybean emulsions in PN</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Adipokines (adiponectin, rezistin leptin and visfatin) and cytokines (IL-6, IL-10, IL-1β and&#xD;
      TNF-α) in critically ill with sepsis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients with sepsis aged 18-85 years given parenteral nutrition therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of sepsis within the last 24 h&#xD;
&#xD;
          -  Age above 18 and below 85 years&#xD;
&#xD;
          -  Indication of only parenteral nutrition therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planning any different medical nutrition therapy such as enteral nutrition,&#xD;
             immunonutrition or oral nutrition&#xD;
&#xD;
          -  Hypersensitivity (fish, egg or soy protein)&#xD;
&#xD;
          -  Uncontrolled hemorrhage&#xD;
&#xD;
          -  Uncontrolled hyperlipidemia&#xD;
&#xD;
          -  Severe primary blood coagulation diseases&#xD;
&#xD;
          -  Acute pancreatitis&#xD;
&#xD;
          -  Acute thromboembolic diseases&#xD;
&#xD;
          -  Severe liver failure&#xD;
&#xD;
          -  RIFLE stage III and IV renal failure&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Expected stay in ICU not more than 10 days&#xD;
&#xD;
          -  Expected survival not more than 10 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melda Kangalgil, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmet Oguzhan Kucuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asiye Ozdemir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Süleyman Caner Karahan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Umitcan Ok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hatice Bozkurt Yavuz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karadeniz Technical University Medical Faculty Department of Anesthesiology and Reanimation</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karadeniz Technical University</investigator_affiliation>
    <investigator_full_name>Hulya ULUSOY</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Parenteral Nutrition</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Adipokines</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Intensive Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
    <mesh_term>Fat Emulsions, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

